Avoid common mistakes on your manuscript.
Correction to: Clinical Journal of Gastroenterology (2022) 16:1–12 https://doi.org/10.1007/s12328-022-01723-4
In the original publication of the article, in page 9, the sixth sentence under the heading “Clinical features of patients with HCC treated with lenvatinib followed by subsequent treatment” should be “In addition, the breakdown of the other subsequent treatment group was as follows: 13 of 33 (39%) patients received TACE, 3 (9%) patients received transarterial chemoinfusion, 5 (15%) patients received R2 resection, 5 (15%) patients received stereotactic or intensity modulated radiation therapy, and the remaining 7 (21%) patients received molecularly targeted agents with or without an immune checkpoint inhibitor (sorafenib; n = 2, ramucirumab; n = 1, and atezolizumab plus bevacizumab; n = 4).”
The Supplementary Table 5 should be replaced as given in this correction.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kawamura, Y., Akuta, N., Shindoh, J. et al. Correction to: Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma. Clin J Gastroenterol 16, 791 (2023). https://doi.org/10.1007/s12328-023-01825-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-023-01825-7